GO:0036151 phosphatidylcholine acyl-chain remodeling: Lipid Remodeling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036151 describes the sequential deacylation and re-acylation of phosphatidylcholine (PC) to diversify its fatty acyl chain composition.
• This remodeling is essential for membrane fluidity, curvature, and the generation of lipid mediators, and it is conserved from yeast to humans.
• Key enzymes include phospholipases A (PLA1/PLA2), lysophospholipid acyltransferases (LPLATs such as LPCAT1-4), and transacylases like tafazzin (TAZ).
• In yeast, PC remodeling is critical for ER homeostasis and is regulated by the Lands cycle and de novo PC synthesis pathways.
• Dysregulation of PC acyl-chain remodeling is linked to metabolic disorders, including nonalcoholic steatohepatitis (NASH) and thyroid hormone-related lipid absorption.
• CRISPR-based knockout, point mutation, and knock-in models are powerful tools to dissect the causal roles of remodeling enzymes in health and disease.
Description
Phosphatidylcholine (PC) is the most abundant phospholipid in eukaryotic membranes, and its acyl chain composition profoundly influences membrane biophysics and cellular signaling. The process of phosphatidylcholine acyl-chain remodeling, annotated as GO:0036151, refers to the enzymatic removal and subsequent re-esterification of fatty acids on the PC glycerol backbone, allowing cells to generate diverse PC molecular species from a limited set of precursors. This remodeling is not merely a housekeeping function; it is a dynamic regulatory mechanism that adjusts membrane properties in response to metabolic and environmental cues. Researchers study GO:0036151 to understand how lipid diversity is generated, how membrane homeostasis is maintained, and how defects in this pathway contribute to human diseases such as metabolic syndrome and cardiovascular disorders. The pathway is highly conserved, with yeast serving as a tractable model for dissecting the enzymatic steps and their regulation. In this article, we integrate authoritative QuickGO annotation with published literature to provide a comprehensive overview of the genes, mechanisms, and research methods associated with phosphatidylcholine acyl-chain remodeling.
phosphatidylcholine acyl-chain remodeling At A Glance
| GO ID | GO:0036151 |
|---|---|
| GO term | phosphatidylcholine acyl-chain remodeling |
| Ontology | biological_process |
| Synonym | phosphatidylcholine acyl-chain remodelling |
| Definition | Remodeling the acyl chains of phosphatidylcholine, through sequential deacylation and re-acylation reactions, to generate phosphatidylcholine containing different types of fatty acid acyl chains. |
| Major function | Diversification of phosphatidylcholine molecular species for membrane homeostasis and signaling. |
| Key enzymes | Phospholipases A (PLA1/PLA2), lysophospholipid acyltransferases (LPLATs), transacylases (e.g., tafazzin). |
| Conservation | Conserved from yeast to humans. |
| Related pathways | Lands cycle, Kennedy pathway, cardiolipin remodeling. |
What Is GO:0036151?
Phosphatidylcholine acyl-chain remodeling (GO:0036151) is the biological process in which the fatty acid chains of phosphatidylcholine are enzymatically removed and replaced with different fatty acids, through sequential deacylation and re-acylation reactions. This process generates phosphatidylcholine molecules with diverse acyl chain compositions, which are critical for membrane function and lipid signaling.
Why Is phosphatidylcholine acyl-chain remodeling Important in Cell Biology?
Phosphatidylcholine acyl-chain remodeling is fundamental to cellular physiology because it determines the biophysical properties of membranes, influences the activity of membrane proteins, and provides precursors for lipid second messengers. Disruptions in this process have been implicated in a wide range of pathologies, from metabolic disorders to neurodegeneration, making it a critical area of biomedical research.
• Maintains membrane fluidity and permeability by adjusting the saturation and length of PC acyl chains.
• Generates lipid mediators such as lysophosphatidylcholine and arachidonic acid derivatives involved in inflammation.
• Supports ER homeostasis and protein folding by regulating lipid bilayer composition.
• Plays a role in cardiolipin remodeling and mitochondrial function through tafazzin-mediated transacylation.
• Contributes to hepatic lipid metabolism and is implicated in nonalcoholic steatohepatitis (NASH).
• Affects thyroid hormone signaling and intestinal lipid absorption.
• Serves as a model for studying enzyme-substrate specificity and lipid trafficking.
• Provides potential therapeutic targets for metabolic and cardiovascular diseases.
What Happens During phosphatidylcholine acyl-chain remodeling?
Deacylation by Phospholipases
In simple terms: First, enzymes cut off one of the fatty acid tails from phosphatidylcholine.
The remodeling cycle begins with the hydrolysis of an acyl ester bond in phosphatidylcholine, catalyzed by phospholipase A1 (PLA1) or phospholipase A2 (PLA2), producing a lysophosphatidylcholine (LPC) intermediate. In yeast, this step is essential for generating substrates for subsequent re-acylation, and mutants defective in deacylation show altered PC species. The activity of these phospholipases is tightly regulated to prevent membrane disruption.
Re-acylation by Acyltransferases
In simple terms: Next, a different fatty acid is attached to the lysophosphatidylcholine, creating a new phosphatidylcholine molecule.
Lysophospholipid acyltransferases (LPLATs), such as LPCAT1-4 in mammals, catalyze the transfer of an acyl-CoA to the sn-2 position of LPC, regenerating PC with a new acyl chain. This step is responsible for incorporating polyunsaturated fatty acids (PUFAs) into PC, which is critical for membrane function and signaling. In yeast, the acyltransferase Ale1p and its homologs perform similar reactions, and their substrate specificity contributes to the diversity of PC species.
Transacylation and Tafazzin
In simple terms: Some enzymes can move fatty acids between lipids without using acyl-CoA, a process called transacylation.
Tafazzin (TAZ) is a transacylase that remodels cardiolipin, but it also influences PC acyl-chain composition by exchanging acyl groups between phospholipids. Studies with liposomes show that tafazzin can directly remodel PC and cardiolipin acyl chains, and its deficiency leads to abnormal lipid profiles. This mechanism is distinct from the Lands cycle and highlights the interconnectedness of phospholipid remodeling pathways.
Substrate Supply and Precursor Incorporation
In simple terms: The building blocks for remodeling come from both newly made lipids and those taken up from outside the cell.
Extracellular phosphatidylcholine with short acyl residues can be incorporated and remodeled in Saccharomyces cerevisiae, indicating that cells can utilize exogenous lipids for remodeling. Mutants defective in de novo and salvage PC synthesis still perform acyl-chain remodeling of dioctanoyl-PC, demonstrating the existence of distinct remodeling pathways. These findings underscore the flexibility of the remodeling machinery in adapting to different lipid sources.
Key Genes Involved in GO:0036151 phosphatidylcholine acyl-chain remodeling
The following genes and proteins are central to phosphatidylcholine acyl-chain remodeling, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G4A | Phospholipase A2, releases arachidonic acid from PC | Inflammation and eicosanoid production |
| PLA1A | Phospholipase A1, generates LPC for re-acylation | Membrane homeostasis and lipoprotein metabolism |
| LPCAT1 | Lysophosphatidylcholine acyltransferase 1, incorporates saturated acyl chains | Lung surfactant and cancer metabolism |
| LPCAT2 | LPCAT2, incorporates arachidonoyl-CoA | Inflammatory signaling |
| LPCAT3 | LPCAT3, incorporates PUFAs into PC | ER stress and metabolic disease |
| LPCAT4 | LPCAT4, acyltransferase with broad specificity | Lipid diversity |
| TAZ | Tafazzin, transacylase remodeling cardiolipin and PC | Barth syndrome and mitochondrial function |
| ALE1 | Yeast acyltransferase, remodels PC and other phospholipids | Model for LPLAT function |
| SLC1 | Yeast lysophospholipid acyltransferase | PC remodeling in ER |
| PLB1 | Yeast phospholipase B, deacylates PC | Lipid turnover |
| NTE1 | Yeast phospholipase, involved in PC deacylation | ER lipid homeostasis |
| CDS1 | CDP-diacylglycerol synthase, links PC and cardiolipin metabolism | Phospholipid crosstalk |
| PIS1 | Phosphatidylinositol synthase, affects PC remodeling | Lipid signaling |
| CHO2 | Yeast phosphatidylethanolamine methyltransferase, affects PC synthesis | PC homeostasis |
| OPI3 | Yeast phospholipid methyltransferase, PC synthesis | Remodeling substrate supply |
| PCT1 | Yeast cholinephosphate cytidylyltransferase, Kennedy pathway | PC synthesis and remodeling |
| CKI1 | Yeast choline kinase, PC synthesis | Precursor supply |
How Is phosphatidylcholine acyl-chain remodeling Regulated?
Phosphatidylcholine acyl-chain remodeling is regulated at multiple levels. In yeast, the process is influenced by the availability of acyl-CoA precursors and the activity of the Kennedy pathway, which supplies PC for remodeling. The expression and activity of phospholipases and acyltransferases are subject to transcriptional and post-translational control, allowing cells to adapt to changing lipid environments. In mammals, thyroid hormone receptor β agonists can ameliorate nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles, indirectly affecting PC remodeling. Additionally, tafazzin-mediated transacylation is regulated by the availability of specific phospholipid substrates and the membrane environment.
phosphatidylcholine acyl-chain remodeling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TAZ | Barth syndrome, mitochondrial dysfunction | TAZ knockout or knock-in cell lines, patient-derived fibroblasts |
| LPCAT3 | NASH, ER stress, metabolic disease | LPCAT3 knockout hepatocytes, mouse models |
| PLA2G4A | Inflammation, cancer | PLA2G4A knockout macrophages, xenograft models |
| LPCAT1 | Lung cancer, surfactant deficiency | LPCAT1 overexpression in lung epithelial cells |
| ALOX15 | Asthma, inflammatory diseases | ALOX15 knockout airway epithelial cells |
Metabolic Disorders and NASH
Dysregulation of phosphatidylcholine acyl-chain remodeling has been linked to nonalcoholic steatohepatitis (NASH). Thyroid hormone receptor β agonists improve NASH by inhibiting intestinal lipid absorption and remodeling bile acid profiles, which may involve changes in PC acyl-chain composition. This suggests that targeting remodeling enzymes could be a therapeutic strategy for metabolic liver diseases.
Barth Syndrome and Mitochondrial Dysfunction
Mutations in the TAZ gene cause Barth syndrome, a rare X-linked disorder characterized by cardiolipin abnormalities and mitochondrial dysfunction. Tafazzin, the product of TAZ, is a transacylase that remodels cardiolipin and also influences PC acyl-chain composition, linking GO:0036151 to mitochondrial pathophysiology.
Inflammation and Cancer
Phospholipase A2 enzymes that deacylate PC release arachidonic acid, a precursor to pro-inflammatory eicosanoids. Overexpression of LPCATs and PLA2s has been observed in various cancers, where altered PC remodeling supports rapid membrane synthesis and signaling. Thus, components of GO:0036151 are potential targets for anti-inflammatory and anticancer therapies.
From phosphatidylcholine acyl-chain remodeling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LPCAT3 affect PC acyl-chain composition? | LPCAT3 knockout HEK293 or HepG2 cells |
| How does TAZ mutation affect cardiolipin and PC remodeling? | TAZ point-mutation knock-in in induced pluripotent stem cells |
| Can overexpression of LPCAT1 alter membrane fluidity? | LPCAT1 overexpression in A549 cells |
| What is the role of yeast ALE1 in PC remodeling? | ALE1 deletion in Saccharomyces cerevisiae |
| Does thyroid hormone receptor β agonist affect PC remodeling? | TRβ agonist-treated hepatocytes and intestinal cells |
| How does extracellular PC incorporation affect remodeling? | Saccharomyces cerevisiae incubated with short-chain PC |
How to Study the phosphatidylcholine acyl-chain remodeling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | PC molecular species and acyl chain composition | Quantifying remodeling in knockout cells |
| CRISPR-Cas9 knockout | Loss-of-function effects on PC remodeling | Validating gene function in cell models |
| CRISPR knock-in | Introduction of specific mutations | Modeling disease-associated variants |
| Fluorescence microscopy | Localization of enzymes and lipid analogs | Visualizing remodeling in live cells |
| Enzymatic activity assay | Deacylation/re-acylation rates | Characterizing enzyme kinetics |
| RNA-seq | Transcriptional changes in remodeling genes | Identifying regulatory networks |
| Proteomics | Protein expression and interactions | Mapping remodeling complexes |
| Yeast genetics | Growth and lipid phenotypes | Functional conservation studies |
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics is the gold standard for quantifying PC molecular species and assessing acyl-chain remodeling. Studies have used this approach to characterize PC profiles in yeast mutants and mammalian cells. It allows researchers to track the incorporation of labeled fatty acids and identify changes in saturation and chain length.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 knockout, point mutation, and knock-in models enable precise interrogation of genes involved in PC remodeling. For example, knockout of LPCAT3 or TAZ can reveal their specific contributions to lipid composition and cellular phenotypes. These models are essential for establishing causality in disease pathways.
Fluorescence Microscopy and Imaging
Imaging techniques using fluorescent lipid analogs or tagged proteins can visualize PC remodeling in live cells. This helps determine the subcellular localization of remodeling enzymes and track lipid trafficking. Yeast models are particularly amenable to fluorescence microscopy due to their defined lipid metabolism.
Enzymatic Assays
In vitro enzymatic assays using recombinant phospholipases and acyltransferases measure deacylation and re-acylation activities. Such assays have been used to characterize tafazzin and LPLATs, providing kinetic parameters and substrate specificity. These methods complement cellular studies and help define molecular mechanisms.
How CRISPR Can Be Used to Study GO:0036151 phosphatidylcholine acyl-chain remodeling
Knockout
CRISPR knockout of genes such as LPCAT3, LPCAT1, or TAZ allows researchers to assess their necessity in phosphatidylcholine acyl-chain remodeling. Knockout cell lines can be analyzed by lipidomics to reveal shifts in PC species and downstream phenotypes. This approach is fundamental for target validation in metabolic and inflammatory diseases.
Point Mutation
Point mutations can be introduced into catalytic residues of remodeling enzymes to dissect their enzymatic activity from scaffolding functions. For example, mutating the active-site serine of LPCATs can abolish acyltransferase activity while preserving protein interactions. Such models are valuable for understanding disease-associated missense variants.
Knock-in
Knock-in of tagged or fluorescently labeled remodeling enzymes enables real-time tracking of their localization and dynamics. This is particularly useful for studying tafazzin and its interaction with cardiolipin in mitochondria. Knock-in models can also introduce human disease mutations into model organisms for functional studies.
Overexpression
Overexpression of remodeling enzymes such as LPCAT1 or PLA2G4A can drive excessive PC remodeling, mimicking pathological states like cancer or inflammation. These models help identify downstream signaling pathways and potential therapeutic interventions.
How EDITGENE Supports phosphatidylcholine acyl-chain remodeling Research
Researchers studying phosphatidylcholine acyl-chain remodeling-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism, membrane homeostasis, or disease. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylcholine acyl-chain remodeling research.
Frequently Asked Questions About phosphatidylcholine acyl-chain remodeling
What is phosphatidylcholine acyl-chain remodeling?
It is the biological process (GO:0036151) of removing and replacing fatty acid chains on phosphatidylcholine to generate diverse lipid species.
What genes are involved in phosphatidylcholine acyl-chain remodeling?
Key genes include LPCAT1-4, PLA2G4A, PLA1A, and TAZ, among others.
What is the role of LPCAT3 in PC remodeling?
LPCAT3 incorporates polyunsaturated fatty acids into phosphatidylcholine, influencing ER stress and metabolic disease.
How is phosphatidylcholine acyl-chain remodeling studied?
Common methods include lipidomics, CRISPR knockout, enzymatic assays, and fluorescence microscopy.
What diseases are linked to defective PC remodeling?
Barth syndrome, nonalcoholic steatohepatitis, inflammation, and cancer have been associated with altered PC remodeling.
What is the Lands cycle?
The Lands cycle is the deacylation-reacylation cycle that remodels phospholipid acyl chains, including phosphatidylcholine.
How does tafazzin contribute to PC remodeling?
Tafazzin is a transacylase that remodels cardiolipin and can also exchange acyl chains on phosphatidylcholine.
Can yeast be used to study PC remodeling?
Yes, Saccharomyces cerevisiae is a powerful model due to conserved remodeling enzymes and tractable genetics.
What are the substrates for PC remodeling?
Lysophosphatidylcholine and acyl-CoAs are the main substrates for re-acylation, while PC itself is the substrate for deacylation.
How does thyroid hormone affect PC remodeling?
Thyroid hormone receptor β agonists can ameliorate NASH by inhibiting intestinal lipid absorption and remodeling bile acid profiles, indirectly affecting PC metabolism.
Conclusion
Phosphatidylcholine acyl-chain remodeling (GO:0036151) is a fundamental biological process that generates lipid diversity and maintains membrane homeostasis. Its dysregulation is implicated in metabolic, mitochondrial, and inflammatory diseases, making it a compelling target for biomedical research. By leveraging CRISPR-based models and advanced lipidomics, researchers can uncover the precise roles of remodeling enzymes and develop novel therapeutic strategies.
References
- 1. Wang B et al.. 2019. Phospholipid Remodeling in Physiology and Disease.. Annu Rev Physiol 81:165-188 PMID: 30379616
- 2. Patton-Vogt J et al.. 2020. Phospholipid turnover and acyl chain remodeling in the yeast ER.. Biochim Biophys Acta Mol Cell Biol Lipids 1865(1):158462 PMID: 31146038
- 3. Renne MF et al.. 2015. Lipid Acyl Chain Remodeling in Yeast.. Lipid Insights 8(Suppl 1):33-40 PMID: 26819558
- 4. Abe M et al.. 2017. Role of Acyl Chain Composition of Phosphatidylcholine in Tafazzin-Mediated Remodeling of Cardiolipin in Liposomes.. Biochemistry 56(47):6268-6280 PMID: 29091407
- 5. Abe M et al.. 2016. Mechanism for Remodeling of the Acyl Chain Composition of Cardiolipin Catalyzed by Saccharomyces cerevisiae Tafazzin.. J Biol Chem 291(30):15491-502 PMID: 27268057
- 6. Tanaka K et al.. 2008. Incorporation and remodeling of extracellular phosphatidylcholine with short acyl residues in Saccharomyces cerevisiae.. Biochim Biophys Acta 1781(8):391-9 PMID: 18599377
- 7. Kishino H et al.. 2014. Acyl-chain remodeling of dioctanoyl-phosphatidylcholine in Saccharomyces cerevisiae mutant defective in de novo and salvage phosphatidylcholine synthesis.. Biochem Biophys Res Commun 445(2):289-93 PMID: 24491568
- 8. Sun K et al.. 2024. A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles.. Acta Pharmacol Sin 45(10):2134-2148 PMID: 38789494
